ESMO Supporter 2018

Found 2 Presentations For Request "LBA44"

Proffered paper session - Melanoma and other skin tumours Proffered Paper session

LBA44 - Overall survival at 4 years of follow-up in a phase 3 trial of nivolumab plus ipilimumab combination therapy in advanced melanoma (CheckMate 067)

Presentation Number
LBA44
Lecture Time
10:00 - 10:15
Speakers
  • F. S. Hodi (Boston, US)
Location
ICM - Room 1, ICM München, Munich, Germany
Date
22.10.2018
Time
09:15 - 10:45

Abstract

Background

Previous results from the CheckMate 067 study demonstrated a significant improvement in objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) with nivolumab plus ipilimumab (NIVO+IPI) and NIVO alone vs IPI alone in patients (pts) with advanced melanoma. Here, we report a 4-year update from CheckMate 067, representing the longest follow-up of a phase 3 study evaluating checkpoint inhibitor combination therapy.

Methods

Treatment-naive pts (N=945) were randomized 1:1:1 to (1) NIVO 1 mg/kg Q3W + IPI 3 mg/kg Q3W for 4 doses, followed by NIVO 3 mg/kg Q2W, (2) NIVO 3 mg/kg Q2W + placebo, or (3) IPI 3 mg/kg Q3W for 4 doses + placebo. Randomization was stratified by PD-L1 status, BRAF mutation status, and M stage. Pts were treated until progression or unacceptable toxicity. Co-primary endpoints were PFS and OS. Secondary endpoints included ORR and safety. While the study was not powered to compare the NIVO-containing groups, secondary objectives also included descriptive efficacy evaluations between NIVO+IPI and NIVO.

Results

At a minimum follow-up of 48 months, NIVO+IPI and NIVO continued to show a higher ORR and improved PFS and OS vs IPI (Table). Time from randomization to subsequent systemic therapy was longest with NIVO+IPI. Among pts alive at 4 years, 71% (113/159), 50% (69/138), and 39% (32/82) in the NIVO+IPI, NIVO, and IPI groups, respectively, were treatment free (off study treatment and had not received subsequent systemic therapy). No new safety signals were observed.

NIVO+IPI
(N=314)

NIVO
(N=316)

IPI
(N=315)

ORR, % (95% CI)

58 (53–64)

45 (39–50)

19 (15–24)

Median PFS, mo (95% CI)

11.5 (8.7–19.3)

6.9 (5.1–10.2)

2.9 (2.8–3.2)

4-year PFS rates, % (95% CI)

37 (31–42)

31 (25–36)

9 (6–13)

Median OS, mo (95% CI)

NR (38.2–NR)

36.9 (28.3–NR)

19.9 (16.9–24.6)

4-year OS rates, % (95% CI)

53 (47–58)

46 (41–52)

30 (25–35)

BRAF mutant

62 (52–71)

50 (39–59)

33 (24–42)

BRAF wild-type

49 (42–55)

45 (38–52)

28 (22–35)

PD-L1 <5%

52 (45–58)

45 (38–52)

28 (22–35)

PD-L1 ≥5%

61 (48–71)

54 (42–64)

36 (25–47)

Median time from randomization to subsequent systemic therapy, mo (95% CI)

NR

25.2 (16.0–43.2)

8.1 (6.5–8.7)

Conclusions

Long-term survival was achieved with NIVO+IPI and NIVO alone in pts with advanced melanoma. Descriptive analyses suggest higher survival rates with NIVO+IPI, and a higher proportion of pts treatment free, than with NIVO alone. First-line NIVO+IPI may reduce the need for subsequent therapy or prolong the time to subsequent therapy when needed.

Clinical trial identification

ClinicalTrials.gov, NCT01844505

Editorial Acknowledgement

Professional medical writing and editorial assistance were provided by Melissa Kirk, PhD, and Cara Hunsberger at StemScientific, an Ashfield Company, funded by Bristol-Myers Squibb.

Collapse
Proffered paper session - Melanoma and other skin tumours Proffered Paper session

Invited Discussant LBA44 and 1244O

Lecture Time
10:30 - 10:45
Speakers
  • Reinhard Dummer (Zurich, CH)
Location
ICM - Room 1, ICM München, Munich, Germany
Date
22.10.2018
Time
09:15 - 10:45